Abstract:Yoona Choi, 1, 2, &ast Bo Kyung Kim, 3, 4, &ast Jung-Hyun Won, 2, 5 Jae Won Yoo, 6 Wona Choi, 7 Surin Jung, 7 Jae Yoon Kim, 7, 8 In Young Choi, 7 Nack-Gyun Chung, 6 Jae Wook Lee, 6 Jung Yoon Choi, 3, 4 Hyoung Jin Kang, 3, 4, 9 Howard Lee 1, 2, 5, 10, 11 1 Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea; 2 Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea; 3 Department of Pediatrics, Seoul National University Hospital, Seoul, Republic of Korea; 4 Seoul National University Cancer Research Institute, Seoul, Republic of Korea; 5 Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea; 6 Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea; 7 Department of Medical Informatics, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea; 8 Department of Biomedicine & Health Sciences, the Catholic University of Korea, Seoul, Republic of Korea; 9 Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea; 10 Advanced Institutes of Convergence Technology, Suwon, Republic of Korea; 11 Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Republic of Korea &astThese authors contributed equally to this work Correspondence: Howard Lee, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea, Email Hyoung Jin Kang, Department of Pediatrics, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea, Email Background: Rapid reduction of leukemic cells in the bone marrow during remission induction chemotherapy (RIC) can lead to significant complications such as tumor lysis syndrome (TLS). We investigated whether prephase steroid treatment before RIC could decrease TLS incidence and improve overall survival in pediatric patients with acute lymphoblastic leukemia (ALL). Methods: Data were extracted from the Common Data Model databases in two tertiary-care hospitals in Seoul, South Korea. Patients were classified into the treated or untreated group if they had received RIC with prephase steroid treatment ≥ 7 days before RIC in 2012– 2021 or not, respectively. Stabilized Inverse Probability of Treatment Weighting (sIPTW) was applied to ensure compatibility between the treated and untreated groups. The incidence of TLS within 14 days of starting RIC, overall survival (OS), and the incidence of adverse events of special interest were the primary endpoints. Multiple sensitivity analyses were performed. Results: Baseline characteristics were effectively balanced between the treated (n=308.4) and untreated (n=246.6) groups after sIPTW. Prephase steroid treatment was associated with a significant 88% reduction in the risk of TLS (OR 0.12, 95% CI: 0.03– 0.41). OS was numerically greater in the treated group than in the untreated group although the difference was not statistically significant (HR 0.64, 95% CI 0.25– 1.64). The treated group experienced significantly elevated risks for hyperbilirubinemia and hyperglycemia. The reduction in TLS risk by prephase steroid treatment was maintained in all of the sensitivity analyses. Conclusion: Prephase steroid treatment for ≥ 7 days before RIC in pediatric patients with ALL reduces the risk of TLS, while careful monitoring for toxicities is necessary. If adequately analyzed, real-world data can provide crucial effectiveness and safety information for proper management of pediatric patients with ALL, for whom prospective randomized studies may be difficult to perform for ethical and practical reasons. Keywords: pediatric acute lymphoblastic leukemia, tumor lysis syndrome, remission induction chemotherapy, prephase steroid treatment, common data model Remission induction chemotherapy (RIC) is the primary treatment for pediatric patients with acute lymphoblastic leukemia (ALL), which aims to quickly reduce the number of leukemic cells in the bone marrow. 1 RIC typically involv -Abstract Truncated-

Severe steroid‐related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy—An observational Ponte di Legno Toxicity Working Group Study

Parents' perception of treatment-related toxicity in children treated according to the NOPHO ALL2008 protocol for acute lymphoblastic leukemia

Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review

Does transitory steroid-induced central hypothyroidism in children treated for haematological malignancies warrant clinical intervention?

Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage

A Study to Evaluate the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Patients with Pediatric Acute Lymphoblastic Leukemia Using Common Data Model-Based Real-World Data: A Retrospective Observational Study

Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)‐induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India

The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE

Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study

Infections Deaths in Acute Lymphoblastic Leukemia More Frequent in High Risk Leukemia

Attention and executive functioning in children and adolescents treated for high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG)

Prognostic significance of steroid response in pediatric acute lymphoblastic leukemia: The CCCG-ALL-2015 study

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation

Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study

Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT

Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions

A case of steroid induced psychosis in a patient with mediastinal lymphoma

Methotrexate might become the sole treatment option for leukemia following the occurrence of Stevens-Johnson syndrome

Intestinal mucositis, systemic inflammation and bloodstream infections following high‐dose methotrexate treatment in childhood acute lymphoblastic leukaemia: Comparison between the NOPHO ALL 2008 protocol and the ALLTogether1 protocol